GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Capex-to-Revenue

Appili Therapeutics (Appili Therapeutics) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Appili Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.36 Mil.

Hence, Appili Therapeutics's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Appili Therapeutics Capex-to-Revenue Historical Data

The historical data trend for Appili Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Capex-to-Revenue Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial - 0.01 - - 0.01

Appili Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Appili Therapeutics's Capex-to-Revenue

For the Biotechnology subindustry, Appili Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Appili Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's Capex-to-Revenue falls into.



Appili Therapeutics Capex-to-Revenue Calculation

Appili Therapeutics's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.002) / 0.244
=0.01

Appili Therapeutics's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.356
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics  (OTCPK:APLIF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Appili Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics (Appili Therapeutics) Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.